Weight-loss drugmakers Eli Lilly (LLY) and Novo Nordisk (NVO) (OTCPK:NONOF) are planning to announce new drug pricing deals with the White House, including for their blockbuster obesity therapies, Endpoints News reported on Tuesday, citing sources familiar with the matter.
If the deals are finalized, Lilly (LLY) and Novo (NVO) will become the latest drugmakers to join the government’s efforts to lower U.S. drug prices in line with President Donald Trump’s most-favored-nation (MFN) pricing policy.
As part of the deal expected to be announced this week, the duo will offer the lowest doses of their weight-loss drugs at $149 per month, and in return, gain Medicare coverage for the products, further widening access to the popular drug class.
Eli Lilly (LLY) and Novo (NVO) were not immediately available for comments. Among major drugmakers, Pfizer (PFE) and AstraZeneca (AZN) have also inked partnerships with the White House to offer their products at sharp discounts to cash-paying customers through a government-run website named TrumpRx.